MGC-026

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameMGC-026

Drug Alias NameVobramitamab tavatecanMGC026MGC-026

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linker

Mechanisms of ActionDNA topoisomerase I inhibitorsCD276 antigen inhibitors

TargetsDNA topoisomerase ICD276 antigen

Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[20]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaUnited Kingdom

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMacrogenics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMacrogenics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[19]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A